Company / Return on Equity (ROE)
Cocrystal Pharma, Inc. Return on Equity (ROE) History
FY2019-FY2021 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Return on Equity (ROE)
-18.3%
FY2021
5-year range
-187.4% / -18.3%
FY2019-FY2021
Trend
+90.2%
vs FY2020
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Cocrystal Pharma, Inc. reports negative total equity of -18.3% in FY2021. Negative equity can occur when accumulated losses exceed contributed capital, as reported in the balance sheet from the SEC filing.
Based on SEC 10-K filings.
-18.3% in FY2021.
Improved from -73.3% to -18.3% over the past 2 years.
Return on Equity (ROE) over time
Growth rates
- 3-Year Change
- -
- 5-Year Change
- -
- 10-Year Change
- -
Key checks
Key Insights
- In FY2021, return on equity (roe) increased 90.2% year-over-year.
Company context
Key Data Points
- Altman Z-Score 14.87 (safe zone, above 2.9 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Return on Equity (ROE)Value | YoY GrowthYoY |
|---|---|---|
| FY2021 | -18.3% | +90.2% |
| FY2020 | -187.4% | -155.5% |
| FY2019 | -73.3% | - |
| FY2012 | - | - |
As of FY2021 · SEC 10-K · Updated Jun 24, 2026